KR20010089538A - Gnrh-ii를 포함하는 조절 방출형 제형 - Google Patents
Gnrh-ii를 포함하는 조절 방출형 제형 Download PDFInfo
- Publication number
- KR20010089538A KR20010089538A KR1020017006883A KR20017006883A KR20010089538A KR 20010089538 A KR20010089538 A KR 20010089538A KR 1020017006883 A KR1020017006883 A KR 1020017006883A KR 20017006883 A KR20017006883 A KR 20017006883A KR 20010089538 A KR20010089538 A KR 20010089538A
- Authority
- KR
- South Korea
- Prior art keywords
- xaa
- peptide
- polymer
- gnrh
- gly
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9826662A GB2344287A (en) | 1998-12-03 | 1998-12-03 | Controlled release pharmaceutical formulation |
GB9826662.0 | 1998-12-03 | ||
PCT/GB1999/004045 WO2000032218A1 (en) | 1998-12-03 | 1999-12-02 | Controlled release formulation comprising gnrh-ii |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20010089538A true KR20010089538A (ko) | 2001-10-06 |
Family
ID=10843631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017006883A KR20010089538A (ko) | 1998-12-03 | 1999-12-02 | Gnrh-ii를 포함하는 조절 방출형 제형 |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1140133A1 (tr) |
JP (1) | JP2002531411A (tr) |
KR (1) | KR20010089538A (tr) |
CN (1) | CN1332635A (tr) |
AU (1) | AU770676B2 (tr) |
BR (1) | BR9915943A (tr) |
CA (1) | CA2353798A1 (tr) |
CZ (1) | CZ20011893A3 (tr) |
EE (1) | EE200100293A (tr) |
GB (1) | GB2344287A (tr) |
HR (1) | HRP20010421A2 (tr) |
HU (1) | HUP0104943A3 (tr) |
IL (1) | IL143496A0 (tr) |
MX (1) | MXPA01005543A (tr) |
NO (1) | NO20012636L (tr) |
NZ (1) | NZ511984A (tr) |
PL (1) | PL348575A1 (tr) |
RU (1) | RU2233170C2 (tr) |
SK (1) | SK7552001A3 (tr) |
TR (1) | TR200102273T2 (tr) |
WO (1) | WO2000032218A1 (tr) |
ZA (1) | ZA200104530B (tr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020196946A1 (ko) * | 2019-03-26 | 2020-10-01 | 노벨파마 주식회사 | 지속형 지방산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물 |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1909814B1 (en) * | 2005-07-26 | 2015-06-24 | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) | Peptides for induction and enhancement of apoptosis in tumor cells |
GB0616111D0 (en) | 2006-06-16 | 2006-09-20 | Ardana Bioscience Ltd | Agents, methods and uses |
CN102448482A (zh) | 2009-03-27 | 2012-05-09 | 范安德尔研究所 | 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法 |
WO2011032099A1 (en) | 2009-09-11 | 2011-03-17 | The Board Of Trustees Of The University Of Illinois | Methods of treating diastolic dysfunction and related conditions |
WO2011056572A1 (en) | 2009-10-27 | 2011-05-12 | The Board Of Trustees Of The University Of Illinois | Methods of diagnosing diastolic dysfunction |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
KR20120123443A (ko) | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-gip 항진제 콘쥬게이트 |
DK2547359T3 (en) | 2010-03-15 | 2016-06-06 | The Board Of Trustees Of The Univ Of Illionis | Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS |
US8940860B2 (en) | 2010-06-16 | 2015-01-27 | Indiana University Research And Technology Corporation | Single-chain insulin agonists exhibiting high activity at the insulin receptor |
US20120004182A1 (en) | 2010-07-02 | 2012-01-05 | Carsten Gruendker | Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells |
EP2655401B1 (en) | 2010-12-20 | 2016-03-09 | The Regents of the University of Michigan | Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction |
ES2713952T3 (es) | 2010-12-22 | 2019-05-24 | Univ Indiana Res & Tech Corp | Análogos de glucagón que muestran actividad de receptor de GIP |
RS56173B1 (sr) | 2011-06-22 | 2017-11-30 | Univ Indiana Res & Tech Corp | Koagonisti receptora za glukagon/glp-1 receptora |
WO2013055791A1 (en) | 2011-10-10 | 2013-04-18 | The Regents Of The University Of Michigan | Polymeric nanoparticles for ultrasound imaging and therapy |
CN103957927B (zh) | 2011-11-17 | 2016-11-09 | 印第安纳大学研究及科技有限公司 | 呈现糖皮质激素受体活性的胰高血糖素超家族肽 |
US9573987B2 (en) | 2011-12-20 | 2017-02-21 | Indiana University Research And Technology Corporation | CTP-based insulin analogs for treatment of diabetes |
WO2013188740A1 (en) | 2012-06-14 | 2013-12-19 | Ambrx, Inc. | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides |
EP2864351B1 (en) | 2012-06-21 | 2016-08-10 | Indiana University Research and Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
WO2013192130A1 (en) | 2012-06-21 | 2013-12-27 | Indiana University Research And Technology Corporation | Analogs of glucagon exhibiting gip receptor activity |
AU2013323669B2 (en) | 2012-09-26 | 2018-03-01 | Indiana University Research And Technology Corporation | Insulin analog dimers |
AU2014241743B2 (en) | 2013-03-14 | 2018-07-05 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
US10189908B2 (en) | 2014-02-05 | 2019-01-29 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants |
US10232020B2 (en) | 2014-09-24 | 2019-03-19 | Indiana University Research And Technology Corporation | Incretin-insulin conjugates |
EP3250609A4 (en) | 2015-01-26 | 2018-07-11 | The University of Chicago | Il13ra alpha 2 binding agents and use thereof in cancer treatment |
CN107835820B (zh) | 2015-01-26 | 2021-10-15 | 芝加哥大学 | 识别癌症特异性IL13Rα2的CAR T细胞 |
CN104789524A (zh) * | 2015-04-30 | 2015-07-22 | 四川大学 | 骨质疏松大鼠原代成骨细胞分离培养方法及应用 |
US20180201937A1 (en) | 2015-08-04 | 2018-07-19 | The University Of Chicago | Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6 |
JP2020505379A (ja) * | 2017-01-20 | 2020-02-20 | イミューン システム レギュレェイション ホールディング エービー | 新規化合物(イムノレリン) |
WO2019006235A1 (en) | 2017-06-30 | 2019-01-03 | Amgen Inc. | METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS |
WO2019028316A1 (en) | 2017-08-03 | 2019-02-07 | Amgen Inc. | INTERLEUKIN-21 MUTÉINS AND METHODS OF TREATMENT |
AR112797A1 (es) | 2017-09-08 | 2019-12-11 | Amgen Inc | Inhibidores de kras g12c y métodos para utilizarlos |
KR20200070238A (ko) | 2017-09-18 | 2020-06-17 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 클라우딘6 항체 및 암치료방법 |
MX2020007291A (es) | 2018-01-12 | 2020-09-10 | Amgen Inc | Anticuerpos anti-pd-1 y metodos de tratamiento. |
WO2020055913A1 (en) | 2018-09-10 | 2020-03-19 | Cardax, Inc. | Methods of reducing- c-reactive protein and/or treating cardiovascular disease |
WO2020191344A1 (en) | 2019-03-20 | 2020-09-24 | The Regents Of The University Of California | Claudin-6 bispecific antibodies |
AU2020241896A1 (en) | 2019-03-20 | 2021-09-23 | The Regents Of The University Of California | Claudin-6 antibodies and drug conjugates |
CA3136496A1 (en) | 2019-04-09 | 2020-10-15 | The Board Of Trustees Of The University Of Illinois | Drug adsorbed highly porous activated carbon for enhanced drug delivery |
WO2020223177A1 (en) | 2019-04-29 | 2020-11-05 | The Board Of Trustees Of The University Of Illinois | Mek inhibitors for corneal scarring and neovascularization |
US20220195059A1 (en) | 2019-04-30 | 2022-06-23 | Instituto de Medicina Molecular João Lobo Antunes | Rank Pathway Inhibitors in Combination with CDK Inhibitors |
CA3140904A1 (en) | 2019-06-24 | 2020-12-30 | Amgen Inc. | Inhibition of sirp-gamma for cancer treatment |
WO2021042048A1 (en) | 2019-08-30 | 2021-03-04 | Research Institute At Nationwide Children's Hospital | Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction |
TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
WO2022159575A1 (en) | 2021-01-20 | 2022-07-28 | Bioentre Llc | Ctla4-binding proteins and methods of treating cancer |
WO2023137161A1 (en) | 2022-01-14 | 2023-07-20 | Amgen Inc. | Triple blockade of tigit, cd112r, and pd-l1 |
US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH661206A5 (fr) * | 1983-09-23 | 1987-07-15 | Debiopharm Sa | Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes. |
DE3414595A1 (de) * | 1984-04-18 | 1985-10-31 | Hoechst Ag, 6230 Frankfurt | Verwendung von gonadoliberin und gonadoliberinagonisten zur behandlung klimakterischer beschwerden |
US4540513A (en) * | 1984-09-25 | 1985-09-10 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Decapeptide having gonadotropin releasing activity |
US4721775A (en) * | 1985-08-26 | 1988-01-26 | Board Of Regents, The University Of Texas System | Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids |
ZA918168B (en) * | 1990-10-16 | 1993-04-14 | Takeda Chemical Industries Ltd | Prolonged release preparation and polymers thereof. |
IT1243390B (it) * | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
CA2192773C (en) * | 1995-12-15 | 2008-09-23 | Hiroaki Okada | Production of sustained-release preparation for injection |
AU3388597A (en) * | 1996-06-13 | 1998-01-07 | University Of Cape Town | Human type ii gonadotropin-releasing hormone receptor |
-
1998
- 1998-12-03 GB GB9826662A patent/GB2344287A/en not_active Withdrawn
-
1999
- 1999-12-02 EP EP99958357A patent/EP1140133A1/en not_active Withdrawn
- 1999-12-02 CZ CZ20011893A patent/CZ20011893A3/cs unknown
- 1999-12-02 BR BR9915943-0A patent/BR9915943A/pt not_active IP Right Cessation
- 1999-12-02 MX MXPA01005543A patent/MXPA01005543A/es unknown
- 1999-12-02 KR KR1020017006883A patent/KR20010089538A/ko not_active Application Discontinuation
- 1999-12-02 CA CA002353798A patent/CA2353798A1/en not_active Abandoned
- 1999-12-02 PL PL99348575A patent/PL348575A1/xx not_active Application Discontinuation
- 1999-12-02 HU HU0104943A patent/HUP0104943A3/hu unknown
- 1999-12-02 AU AU15732/00A patent/AU770676B2/en not_active Ceased
- 1999-12-02 NZ NZ511984A patent/NZ511984A/xx unknown
- 1999-12-02 JP JP2000584909A patent/JP2002531411A/ja active Pending
- 1999-12-02 EE EEP200100293A patent/EE200100293A/xx unknown
- 1999-12-02 IL IL14349699A patent/IL143496A0/xx unknown
- 1999-12-02 WO PCT/GB1999/004045 patent/WO2000032218A1/en not_active Application Discontinuation
- 1999-12-02 CN CN99815183A patent/CN1332635A/zh active Pending
- 1999-12-02 RU RU2001118040/15A patent/RU2233170C2/ru not_active IP Right Cessation
- 1999-12-02 TR TR2001/02273T patent/TR200102273T2/tr unknown
- 1999-12-02 SK SK755-2001A patent/SK7552001A3/sk unknown
-
2001
- 2001-05-29 NO NO20012636A patent/NO20012636L/no not_active Application Discontinuation
- 2001-06-01 ZA ZA200104530A patent/ZA200104530B/en unknown
- 2001-06-01 HR HR20010421A patent/HRP20010421A2/hr not_active Application Discontinuation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020196946A1 (ko) * | 2019-03-26 | 2020-10-01 | 노벨파마 주식회사 | 지속형 지방산 결합 GnRH 유도체 및 이를 포함하는 약제학적 조성물 |
AU2019437315B2 (en) * | 2019-03-26 | 2022-10-06 | Novel Pharma Inc. | Long-acting fatty acid-binding GnRH derivative and pharmaceutical composition comprising same |
US11975048B2 (en) | 2019-03-26 | 2024-05-07 | Novel Pharma Inc. | Long-acting fatty acid-conjugated GnRH derivatives and pharmaceutical compositions containing same |
Also Published As
Publication number | Publication date |
---|---|
PL348575A1 (en) | 2002-06-03 |
MXPA01005543A (es) | 2003-07-14 |
IL143496A0 (en) | 2002-04-21 |
NO20012636D0 (no) | 2001-05-29 |
ZA200104530B (en) | 2002-06-04 |
EP1140133A1 (en) | 2001-10-10 |
BR9915943A (pt) | 2001-08-21 |
JP2002531411A (ja) | 2002-09-24 |
NZ511984A (en) | 2002-11-26 |
GB9826662D0 (en) | 1999-01-27 |
NO20012636L (no) | 2001-07-12 |
CN1332635A (zh) | 2002-01-23 |
AU1573200A (en) | 2000-06-19 |
GB2344287A (en) | 2000-06-07 |
EE200100293A (et) | 2002-08-15 |
AU770676B2 (en) | 2004-02-26 |
TR200102273T2 (tr) | 2001-12-21 |
WO2000032218A1 (en) | 2000-06-08 |
SK7552001A3 (en) | 2002-02-05 |
CZ20011893A3 (cs) | 2002-05-15 |
HUP0104943A2 (en) | 2002-06-29 |
RU2233170C2 (ru) | 2004-07-27 |
CA2353798A1 (en) | 2000-06-08 |
HUP0104943A3 (en) | 2002-08-28 |
HRP20010421A2 (en) | 2002-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20010089538A (ko) | Gnrh-ii를 포함하는 조절 방출형 제형 | |
CA1339043C (en) | Nonapeptide and decapetide analogs of lhrh useful as lhrh antagonists | |
US5084555A (en) | An octapeptide bombesin analog | |
AU638423B2 (en) | Therapeutic peptides | |
US5877277A (en) | Octapeptide bombesin analogs | |
CA2097192C (en) | Bombesin antagonists | |
US5217955A (en) | Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin | |
KR100306506B1 (ko) | 폴리펩티드봄베신길항제 | |
US7189692B2 (en) | Synthetic peptides and pseudopeptides having osteogenic activity and pharmaceutical compositions containing the same | |
US5736517A (en) | Treatment of cancer with peptides | |
EP1124847B1 (en) | Lhrh analogues for the treatment of osteoporosis | |
EP0452447A1 (en) | Reduced irreversible bombesin antagonists | |
US5439884A (en) | Method of controlling fertilization using bombesin or its agonist | |
NL8300413A (nl) | Groeihormoon vrijstellend peptide. | |
AU2710288A (en) | Therapeutic peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |